Preventing Cognitive Decline by Reducing BP Target Trial

NARecruitingINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Cognitive DeclineBlood PressureHypertension
Interventions
OTHER

Clinical Support Decision Tool

Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.

Trial Locations (1)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Duke University

OTHER

collaborator

Parkland Health and Hospital System

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT05106036 - Preventing Cognitive Decline by Reducing BP Target Trial | Biotech Hunter | Biotech Hunter